To study the potential role of Platelet Rich Plasma (centrifuged whole blood) as a therapeutic modality in Melasma (patchy brown discoloration of face)

To study the potential role of Platelet Rich Plasma as a therapeutic modality in Melasma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/09/027525

Enrollment

Registered

2020-09-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue

Interventions

Intervention1: To study the potential role of Platelet Rich Plasma as a therapeutic modality in Melasma: Patient blood is withdrawn, then centrifuged to seperate the plasma. After applying topical an

Eligibility

Inclusion criteria

Inclusion criteria: Age > 18 years Non Pregnant and Non lactating women Patients not taking oral contraceptives. Patients with no history of chronic liver disease, thromboembolism, bleeding disorders, and abnormal coagulation profile; on antiplatelet, anticoagulant or systemic chemotherapy. Patients with no history of hypertrophic scars or keloids, recurrent herpes infection or current cutaneous infection Patients with no history psychological disorders Patients who have not taken any other melasma therapy within last 3 months.

Exclusion criteria

Exclusion criteria: Age less than 18 years Pregnant and lactating women Patients taking oral contraceptives Patients with history of chronic liver disease, thromboembolism, bleeding disorders, and abnormal coagulation profile; on antiplatelet, anticoagulant or systemic chemotherapy Patients with history of hypertrophic scars or keloids, recurrent herpes infection or current cutaneous infection Patients with psychological disorders Patients having unrealistic expectation from the treatment Patients who have taken any other melasma therapy within last 3 months

Design outcomes

Primary

Measure	Time frame
The Modified Melasma Assessment Severity Index (mMASI) score will be the primary outcome measure.Timepoint: It will be determined during the start of treatment (baseline) and at the end of 4, 8, 12, 16 and 24 weeks.	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Karaninder Singh Mehta

Dr RPG Medical College Kangra

vijaykaransingh136@gmail.com9592732862

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026